In recent years, proteasome inhibitors have been widely applied in the treatment of multiple myeloma (MM), demonstrating significant therapeutic value. However, these drugs face numerous clinical challenges, such as short circulation half-life, poor water solubility, patient resistance, and severe adverse events. Nanoparticles for targeted drug delivery, with unique advantages, have shown promise as an effective solution to these issues. This paper reviews the mechanisms of nanotargeted drug delivery for proteasome inhibitors and the progress of their use in MM treatment both domestically and internationally, aiming to provide a reference for researchers in related fields.

In recent years, proteasome inhibitors have been widely applied in the treatment of multiple myeloma (MM), demonstrating significant therapeutic value. However, these drugs face numerous clinical challenges, such as short circulation half-life, poor water solubility, patient resistance, and severe adverse events. Nanoparticles for targeted drug delivery, with unique advantages, have shown promise as an effective solution to these issues. This paper reviews the mechanisms of nanotargeted drug delivery for proteasome inhibitors and the progress of their use in MM treatment both domestically and internationally, aiming to provide a reference for researchers in related fields.